Strong Profit Growth at Amaya (AYA); Stifel Sees Upside on Gilead Sciences (GILD)

Amaya, Inc. (Nasdaq:AYA) shares climbed more than 10% in pre-market trade Monday after the PokerStars owner delivered a robust growth in profits in its quarterly financial results

For the third quarter 2016, Amaya posted revenues of $270.85 million, a 9.5% increase year over year, and adjusted net income of $84.98 million, or $0.42 per diluted share versus an adjusted net income of $69.02 million, or $0.35 per diluted share in the same period the prior year

According to its business outlook for the full year 2016, Amaya expects revenues to be in the range of $1.14 million to $1.16 million and adjusted net earnings to be between $344 million, or $1.78 per diluted share and $354 million, or $1.83 per diluted share for the period

AYA stock finished Friday’s trading session at $13.60 and 112,310 of its shares changed hands during the day

Amaya, which provides technology-based products and services to the global gaming and interactive entertainment industries, has 144.88M Shares Outstanding and AYA stock 52-week range is between $9.67 and $17.57 per share. At close on Friday, the company had a Market Capitalization of $1.97B



Investment analysts at Stifel initiated coverage on Gilead Sciences, Inc. (Nasdaq:GILD) shares with a Buy rating and a price target of $100.00, representing a potential upside of 30.8% from the stock’s closing price on Friday of $76.44

The research-based biopharmaceutical company recently reported third quarter 2016 sales of $7.4 billion and non-GAAP net income of $3.68 billion, or $2.75 per diluted share for the period

Gilead Sciences, which discovers, develops, and commercializes medicines in areas of unmet medical needs. has 1.32B Shares Outstanding, Market Capitalization (intraday) of $100.68B and GILD stock one-year range is from $71.39 to $108.63 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at